Diabetes and obesity
Retatrutide trial finds weight loss in adults with diabetes and obesity
In an 80-week phase 3 trial, retatrutide 12 mg was linked to 18.8% weight loss, versus 5.1% with placebo, in adults with type 2 diabetes and overweight or obesity.

An 80-week phase 3 trial found that once-weekly retatrutide was associated with weight loss and improved blood sugar control in adults with type 2 diabetes and overweight or obesity, Healio and Medical Xpress reported. The investigational drug was tested against placebo.
Among 1,152 participants, average weight loss at 80 weeks was 11.9% with 4 mg, 16.8% with 9 mg and 18.8% with 12 mg, compared with 5.1% with placebo, using the treatment-regimen estimate reported by Healio. Healio also reported weight loss of 20.8% with 12 mg using the efficacy estimate. HbA1c fell by 1.45 percentage points with 12 mg, versus 0.45 percentage points with placebo.
Gastrointestinal events were the most common side effects. Discontinuation due to adverse events or death was reported in 12% of participants taking 9 mg and 8% taking 12 mg, compared with 5% receiving placebo. Healio reported that five further phase 3b trials are underway.


